abhishreshthaa

New member
Bristol-Myers Squibb , often referred to as BMS, is a pharmaceutical company, headquartered in New York City. The company was formed in 1989, following the merger of its predecessors Bristol-Myers and the Squibb Corporation. Squibb was founded in 1858 by Edward Robinson Squibb in Brooklyn, New York, while Bristol-Myers was founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, New York (both were graduates of Hamilton College).

Lamberto Andreotti became the company's CEO on May 4, 2010. Former CEO James M. Cornelius remains chairman of the Board of Directors.

Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. Its mission is to "discover, develop and deliver innovative medicines that help patients prevail over serious diseases." Over the past several years BMS had been upping the price of its medicines to bolster profits. In 2008 Sprycel gained notoriety as the drug with the largest annual price increase, at 32%.

Strengths
  • Industry leaders
  • Strong sales and marketing infrastructure
  • Revived blockbuster credentials in recent years - Lyrica, Sutent and Chantix/Champix
  • Strong R&D departments
  • R&D innovation with a broad therapeutic coverage
  • Marketing strength in major geographical and therapeutic areas
  • Existing Patent protection for a number of years on key products
    jews
    Weaknesses

    * Drought in blockbuster launches between
    1999 and 2004 (masked by M&A activity)
    * Entrenchment in low growth therapy area
    markets such as CV and CNS
    * Very limited penetration of biologics market
    * Discontinuation of products in the latter stages of development
    * Co-marketing agreements can limit Pfizer's global presence

    Opportunities

    * Restructuring strategy designed to cut costs and create a leaner company
    * Funding available to facilitate product/company
    * Acquisitions and in-licensing/co- development opportunities
    * Biologic market expansion
    * Decreasing development time through favorable R&D collaborations and internal efforts
    * Emergence of integrated global markets and globalisation for new products
    * Co-marketing agreements with companies wishing to capitalize on Pfizer's marketing
    * Strengths, providing Pfizer with strong products and therefore revenue growth

    Threats

    * Considerable exposure to generic competition, focal point of which is Lipitor, due to lose patent exclusivity in 2011
    * Further large scale M&A activity could further decline Pfizer's profitability
    * Increased competition for core products like Viagra as its high cost encourages use of cheaper alternative treatments
    * An increase in the number of safety issues surrounding Viagra
    * Competition from products similar to Pfizer's in R&D that reach the market close to or before Pfizer's products
    * The new economic potential of emergent China, India and competition in diverse regional markets.
    * Economic downturn influencing consumers' purchasing power
    * Negative publicity
    Losing the quality of their drugs and being sued by more consumers.
 
Top